Search
for
Sort by
Research 601–630 of 993
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Chinese Herbal Medicine for Reducing Chemotherapy-Associated Side-Effects in Breast Cancer Patients: A Systematic Review and Meta-Analysis
- 9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Treatment of pediatric alopecia areata: A systematic review
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients
- MicroRNA-Enriched Exosomes from Different Sources of Mesenchymal Stem Cells Can Differentially Modulate Functions of Immune Cells and Neurogenesis
- Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
- Alopecia and Associated Toxic Agents: A Systematic Review
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Expanding phenotype of hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis caused by FAM111B mutations: Report of an additional family raising the question of cancer predisposition and a short review of early-onset poikiloderma
- Minimizing Skin Scarring through Biomaterial Design
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4
- Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus
- The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19
- Prophylaxis and Management of Skin Toxicities
- Lithium: one drug, five complications
- A.S.P.E.N. Parenteral Nutrition Trace Element Product Shortage Considerations
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
- Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review)
- Further Insights in Trichothiodistrophy: A Clinical, Microscopic, and Ultrastructural Study of 20 Cases and Literature Review
- Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine